Taysha Gene Therapies, Inc. (TSHA) stock forecast and price target
Price $4.10 · data as of November 13, 2026
12-month price target
Average target$13.00
Upside / downside+217.1%
Analysts13
ConsensusStrong buy
Low $9.00Average $13.00High $19.00
Gold marker: average target · white marker: today’s price ($4.10)
Analyst ratings
Strong buy 3Buy 10Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.43 | −35.9% | $333330 |
| Next fiscal year ends December 31, 2027 | $-0.39 | +10.3% | $14M |
| Next quarter ends December 31, 2026 | $-0.10 | −43.5% | $375000 |
| Quarter after ends March 31, 2027 | $-0.10 | +6.0% | $685710 |
Consensus of the analysts covering Taysha Gene Therapies, updated daily. In the last 30 days 0 estimates were raised and 3 lowered.
Frequently asked questions
What is the Taysha Gene Therapies stock price target?
The average 12-month target from 13 analysts is $13.00, 217.1% above the current price of $4.10 Targets range from $9.00 to $19.00.
Is Taysha Gene Therapies a buy according to analysts?
The consensus rating is “Strong buy” (3 strong buy, 10 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Taysha Gene Therapies expected to earn?
Analysts expect EPS of $-0.43 for the fiscal year ending December 31, 2026 and $-0.39 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.